DICIÍ RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

Acinetobacter baumannii, Strain MRSN 3360

Catalog No. NR-52161

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 3360 was isolated in 2011 from a human blood sample in the United States as part of a global surveillance program. NR-52161 was deposited as multi-locus sequence type (MLST) ST 499, sensitive to amikacin, ceftazidime, colistin and ceftriaxone, intermediately resistant to tobramycin and tetracycline and resistant to ciprofloxacin, cefepime, gentamicin, imipenem, levofloxacin, meropenem, ampicillin/sulbactam and trimethoprim/sulfamethoxazole. NR-52161 lot 70058390 was produced by inoculation of BEI Resources seed lot 70038544 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70058390

Manufacturing Date: 27JAN2023

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram- negative rods	Gram- negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream
Growth at 44°C ± 2°C ¹ 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Hardy Diagnostics™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile
VITEK [®] MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)
Antibiotic Susceptibility Profile ^{2,3}		
Amikacin	Sensitive	Sensitive (3 µg/mL)
Ampicillin/sulbactam	Intermediate	Sensitive (4 µg/mL) ⁴
Cefepime	Resistant	Resistant (32 µg/mL)
Ceftriaxone	Sensitive	Intermediate (16 µg/mL) ⁵
Ceftazidime	Sensitive	Sensitive (3 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Gentamicin	Resistant	Resistant (16 µg/mL)
Imipenem	Resistant	Resistant (≥ 32 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Tobramycin	Intermediate	Sensitive (2 to 3 μ g/mL) ⁶
Tetracycline	Resistant	Resistant (48 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>A. baumannii</i> , strain MRSN 3360 (GenBank: VHEZ01000039.1)	100% sequence identity to <i>A. baumannii</i> , strain MRSN 3360 (GenBank: VHEZ01000039.1)

b|**e**|**i** resources

Certificate of Analysis for NR-52161

SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Purity (post-freeze) 8 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)	Growth	Growth

¹Growth at 44°C differentiates A. baumannii from A. calcoaceticus and A. pittii, which do not grow at 44°C.

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³Antibiotic susceptibility was tested using a combination of VITEK[®]2 GN81 and E-test strips.

⁴A. baumannii, strain MRSN 3360 was deposited as resistant to ampicillin/sulbactam and was found to be intermediate in the previous lot but showed a MIC of 4 µg/mL (interpreted as sensitive) during QC testing. Testing was performed in triplicate.

⁵The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁶A. baumannii, strain MRSN 3360 was deposited as intermediately resistant to tobramycin but showed a MIC of 2 to 3 μg/mL (interpreted as sensitive) for tobramycin during QC testing. Testing was performed in duplicate.

/Sonia Bjorum Brower/

Sonia Biorum Brower

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.





06 JUN 2023